Denosumab: A promising drug for the prevention and treatment of osteoporosis

Women's Health

Volumn 2, Issue 4, 2006, Pages 517-525

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

AMG 162; Denosumab; OPG; Osteoporosis; Prevention; RANK; RANKI

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RECOMBINANT PARATHYROID HORMONE; RECOMBINANT PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE TURNOVER; BREAST CANCER; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DYSPEPSIA; FRACTURE; HUMAN; INFECTION; INJECTION SITE REACTION; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION;

EID: 33745604904     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.4.517     Document Type: Review

References (43)

1. Melton LJ III: How many women have osteoporosis now? J. Bone Miner. Res. 10, 175-177 (1995).
2. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL: Perspective. How many women have osteoporosis? J. Bone Miner. Res. 7, 1005-1010 (1992).
3. Johnell O, Kanis JA: An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos. Int 15, 897-902 (2004).
4. Johnell O, Kanis JA, Oden A et al.: Fracture risk following an osteoporotic fracture. Osteoporos. Int. 15, 175-179 (2004).
5. Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T: Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures - a gap in evidence-based practice guideline implementation. Arch. Intern. Med. 163, 2165-2172 (2003).
6. Feldstein AC, Nichols GA, Elmer PJ, Smith DH, Aickin M, Herson M: Older women with fractures: Patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J. Bone Joint Surg. Am. 85A, 2294-2302(2003).
7. McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J: Compliance with drug therapies for the treatment and prevention of asteoporosis. Maturitas 48, 271-287 (2004).
8. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E: Compliance with pharmacologic therapy for osteoporosis. Osteoporos. Int. 14, 965-968 (2003).
9. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C: The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos. Int. 15, 1003-1008 (2004).
10. US Department of Health and Human Services: Bone Health and Osteoporosis: A report ofthe Surgeon General. US Department of Health and Human Services, Office of the Surgeon General, Rockville, MD, USA (2004).
11. Bekker PJ, Holloway DL, Rasmussen AS et al.: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059-1066 (2004).
12. Body JJ, Facon T, Coleman RE et al.: A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12, 1221-1228 (2006).
13. McClung MR, Lewiecki EM, Cohen SB et al.: Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821-831 (2006).
14. Riggs BL, Parfitt AM: Drugs Tsed to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. 20, 177-184 (2005).
15. Riggs BL, Melton LJ III, O'Fallon WM: Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18(Suppl. 3), S197-S201 (1996).
16. McClung MR, San MJ, Miller PD et al.: Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 165, 1762-1768 (2005).
17. Meunier PJ, Slosman DO, Delmas PD et al.: Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 87, 2060-2066 (2002).
18. Felsenberg D, Boonen SD The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin. Ther. 27, 1-11 (2005).
19. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 423, 337-342 (2003).
20. Collin-Osdoby P: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ. Res. 95, 1046-1057 (2004).
21. Simonet WS,ALacey DL, Dunstan CR et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
22. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 292, 490-495 (2004).
23. Neumann E, Gay S, Muller-Ladner U: The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: New insights from animal models. Arthritis Rheum. 52, 2960-2967 (2005).
24. Clowes JA, Riggs BL, Khosla S: The role of the immune system in the pathophysiology of osteoporosis. Immunol. Rev. 208, 207-227 (2005).
25. Whyte MP: The long and the short of bone therapy. N. Engl. J. Med. 354, 860-863 (2006).
26. Dougall WC, Glaccum M, Charrier K et al.: RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424 (1999).
27. Stolina M, Dwyer D, Morony S et al.: Rats and mice overexpressing soluble OPG have high bone mass but no alteration in immunological parameters or lymphocyte function. Arthritis Rheum. S708 (2005).
28. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR: The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16, 348-360 (2001).
29. Fisher JL, Thomas-Mudge RJ, Elliott J et al.: Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 66, 3620-3628 (2006).
30. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET: Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res. 63, 7883-7890 (2003).
31. Jones DH, Nakashima T, Sanchez OH et al.: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696 (2006).
32. Peterson MC, Stouch BJ, Martin SW et al.: The pharmacokinetics of denosumab (AMG 162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass. J. Bone Miner. Res. 20(Suppl. 1), S293 (2005).
33. Body JJ, Greipp P, Coleman RE et al.: A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97, 887-892 (2003).
34. Mankarious S, Lee M, Fischer S et al.: The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J. Lab. Clin. Med. 112, 634-640 (1988).
35. Matsuzaki K, Udagawa N, Takahashi N et al.: Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Commun. 246, 199-204 (1998).
36. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140, 4367-4370 (1999).
37. Bucay N, Sarosi I, Dunstan CR et al.: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268 (1998).
38. Kong YY, Yoshida H, Sarosi I et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
39. Li J, Sarosi I, Yan XQ et al.: RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc.. Natl Acad. Sci. USA 97, 1566-1571 (2000).
40. Ross AB, Bateman TA, Kostenuik PJ et al.: The effects of osteoprotegerin on the mechanical properties of rat bone. J. Mater. Sci. Mater. Med. 12, 583-588 (2001).
41. Kostenuik PJ, Capparelli C, Morony S et al.: OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142, 4295-4304 (2001).
42. Cohen SB, Lewiecki EM, Liu Y, Zach DJ, Fitzpatrick LA: Phase 2 study of denosumab (AMG 162) in postmenopausal women: Subanalyses and supplemental safety. J. Bone Miner. Res. 20(Suppl. 1), S295 (2005).
43. Kostenuik PJ: Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr. Opin. Pharmacol. 5, 618-625 (2005).